Tags

Type your tag names separated by a space and hit enter

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Gastroenterology. 2010 Jan; 138(1):116-22.G

Abstract

BACKGROUND & AIMS

Patients with chronic hepatitis C virus (HCV) infection are frequently treated with a combination of pegylated interferon (peginterferon) and ribavirin. This study compared the efficacy and safety of peginterferon alfa-2a and peginterferon alfa-2b, each in combination with ribavirin.

METHODS

A total of 320 consecutive, treatment-naive, HCV RNA-positive patients with chronic hepatitis were randomly assigned to once-weekly peginterferon alfa-2a (180 microg, group A) or peginterferon alfa-2b (1.5 microg/kg, group B) plus ribavirin 1000 mg/day (body weight <75 kg) or 1200 mg/day (body weight >or=75 kg) for 48 weeks (genotype 1 or 4) or 24 weeks (genotype 2 or 3). The primary end point was sustained virological response (SVR) by intention-to-treat.

RESULTS

More patients in group A than group B achieved an SVR (110/160 [68.8%] vs 87/160 [54.4%]; P = .008). Higher SVR rates were obtained in group A than group B among patients with genotype 1/4 (51/93 [54.8%] vs 37/93 [39.8%]; P = .04), with genotype 2/3 (59/67 [88.1%] vs 50/67 [74.6%]; P = .046), without cirrhosis (96/127 [75.6%] vs 75/134 [55.9%]; P = .005), and with baseline levels HCV RNA >500,000 IU/mL (58/84 [69%] vs 43/93 [46.2%]; P = .002). SVR rates in groups A and B were not statistically different among patients with baseline HCV RNA <or=500,000 IU/mL (52/76 [68.4%] vs 44/67 [65.7%]; P = .727) or in patients with cirrhosis (14/33 [42.4%] vs 12/26 [46.1%]; P = .774).

CONCLUSIONS

In patients with chronic HCV infection, peginterferon alfa-2a plus ribavirin produced a significantly higher SVR rate than peginterferon alfa-2b plus ribavirin.

Authors+Show Affiliations

Department of Gastroenterology, Liver Unit, Cardarelli Hospital, Napoli, Italy. antonio.ascione@mail.healthware.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19852964

Citation

Ascione, Antonio, et al. "Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection." Gastroenterology, vol. 138, no. 1, 2010, pp. 116-22.
Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010;138(1):116-22.
Ascione, A., De Luca, M., Tartaglione, M. T., Lampasi, F., Di Costanzo, G. G., Lanza, A. G., Picciotto, F. P., Marino-Marsilia, G., Fontanella, L., & Leandro, G. (2010). Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology, 138(1), 116-22. https://doi.org/10.1053/j.gastro.2009.10.005
Ascione A, et al. Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology. 2010;138(1):116-22. PubMed PMID: 19852964.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. AU - Ascione,Antonio, AU - De Luca,Massimo, AU - Tartaglione,Maria Teresa, AU - Lampasi,Filippo, AU - Di Costanzo,Giovan Giuseppe, AU - Lanza,Alfonso Galeota, AU - Picciotto,Francesco Paolo, AU - Marino-Marsilia,Giuseppina, AU - Fontanella,Luca, AU - Leandro,Gioacchino, Y1 - 2009/10/20/ PY - 2009/03/23/received PY - 2009/10/11/revised PY - 2009/10/15/accepted PY - 2009/10/27/entrez PY - 2009/10/27/pubmed PY - 2010/3/17/medline SP - 116 EP - 22 JF - Gastroenterology JO - Gastroenterology VL - 138 IS - 1 N2 - BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection are frequently treated with a combination of pegylated interferon (peginterferon) and ribavirin. This study compared the efficacy and safety of peginterferon alfa-2a and peginterferon alfa-2b, each in combination with ribavirin. METHODS: A total of 320 consecutive, treatment-naive, HCV RNA-positive patients with chronic hepatitis were randomly assigned to once-weekly peginterferon alfa-2a (180 microg, group A) or peginterferon alfa-2b (1.5 microg/kg, group B) plus ribavirin 1000 mg/day (body weight <75 kg) or 1200 mg/day (body weight >or=75 kg) for 48 weeks (genotype 1 or 4) or 24 weeks (genotype 2 or 3). The primary end point was sustained virological response (SVR) by intention-to-treat. RESULTS: More patients in group A than group B achieved an SVR (110/160 [68.8%] vs 87/160 [54.4%]; P = .008). Higher SVR rates were obtained in group A than group B among patients with genotype 1/4 (51/93 [54.8%] vs 37/93 [39.8%]; P = .04), with genotype 2/3 (59/67 [88.1%] vs 50/67 [74.6%]; P = .046), without cirrhosis (96/127 [75.6%] vs 75/134 [55.9%]; P = .005), and with baseline levels HCV RNA >500,000 IU/mL (58/84 [69%] vs 43/93 [46.2%]; P = .002). SVR rates in groups A and B were not statistically different among patients with baseline HCV RNA <or=500,000 IU/mL (52/76 [68.4%] vs 44/67 [65.7%]; P = .727) or in patients with cirrhosis (14/33 [42.4%] vs 12/26 [46.1%]; P = .774). CONCLUSIONS: In patients with chronic HCV infection, peginterferon alfa-2a plus ribavirin produced a significantly higher SVR rate than peginterferon alfa-2b plus ribavirin. SN - 1528-0012 UR - https://www.unboundmedicine.com/medline/citation/19852964/Peginterferon_alfa_2a_plus_ribavirin_is_more_effective_than_peginterferon_alfa_2b_plus_ribavirin_for_treating_chronic_hepatitis_C_virus_infection_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(09)01811-3 DB - PRIME DP - Unbound Medicine ER -